慢肝合剂抗肝纤维化的临床研究

Clinical Trial of Mangan Mixture Against Hepatic Fibrosis

目的 探讨慢肝合剂治疗慢性乙型肝炎肝纤维化的临床疗效。方法 选择 4 5例慢性乙肝患者随机分为治疗组和对照组 ,分别观察两组治疗前后的症状体征、肝功能、肝脾B超、乙肝病毒标志物 (HBVM)、透明质酸 (HA)、层粘连蛋白 (LN)、Ⅳ型胶原 (CⅣ )。结果 治疗组上述指标的改善情况明显优于对照组 (P <0 0 1) ,治疗组有效率为 93 3% ,对照组有效率为 6 6 7%。

Objective To investigate the curative effects of Mangan Mixture (MM) on hepatic fibrosis in chronic hepatitis B. Methods 45 Patients with chronic hepatitis B were randomly divided into the MM treating group and control group. The criteria, such as clinical symptoms and signs, indexes of hepatic function, hepatic and splenic indexes of ultrasonic wave B, HBVM, HA, LN and CIV were observed before and after the treatment in both groups. Results The degree of improvement in all above criteria in the MM treating group was obviously larger than that in the control group (P<0.01). The effective rate with the MM treating group was 93.3%, and that with the control group was 66.7%. Conclusion MM is an effective TCM formula for treating hepatic fibrosis in chronic hepatitis B.